Difference between revisions of "Papillary renal neoplasm with reverse polarity"
Jump to navigation
Jump to search
(distinct from pRCC) |
|||
| Line 3: | Line 3: | ||
==General== | ==General== | ||
*Evolving entity. | *Evolving entity. | ||
* | *Thought to be distinct from ''eosinophilic [[papillary renal cell carcinoma]]''.<ref name=pmid38456605>{{cite journal |authors=Castillo VF, Trpkov K, Van der Kwast T, Rotondo F, Hamdani M, Saleeb R |title=Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma |journal=Pathol Int |volume=74 |issue=4 |pages=222–226 |date=April 2024 |pmid=38456605 |doi=10.1111/pin.13417 |url=}}</ref> | ||
==Micro== | ==Micro== | ||
Revision as of 18:51, 17 June 2024
Papillary renal neoplasm with reverse polarity is a rare renal tumour and evolving entity.[1]
General
- Evolving entity.
- Thought to be distinct from eosinophilic papillary renal cell carcinoma.[2]
Micro
Features:[1]
- Branching papillae with:
- Thin fibrovascular cores.
- Cuboidal to columnar lining cells with granular eosinophilic cytoplasm.
- May have occasional cytoplasmic clearing.
- Smooth luminal borders.
- Reverse polarized nuclei (luminal nuclei; nuclei closer to lumen than basement membrane).
- Nucleoli absent or small.
DDx:
IHC
Features:[1]
- CK7 +ve.
- CD10 +ve (all cases).
- GATA3 +ve (all cases).
- Vimentin -ve (all cases).
- CD117 -ve.
- AE1/AE3 +ve.
- EMA +ve.
- L1CAM +ve.
See also
References
- ↑ 1.0 1.1 1.2 Al-Obaidy KI, Eble JN, Cheng L, Williamson SR, Sakr WA, Gupta N, Idrees MT, Grignon DJ (August 2019). "Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study". Am J Surg Pathol 43 (8): 1099–1111. doi:10.1097/PAS.0000000000001288. PMID 31135486.
- ↑ Castillo VF, Trpkov K, Van der Kwast T, Rotondo F, Hamdani M, Saleeb R (April 2024). "Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma". Pathol Int 74 (4): 222–226. doi:10.1111/pin.13417. PMID 38456605.